TMEM41A and neoplasm: Specifically, TMEM41A overexpression was associated with shorter OS (Fig 3) in patients with EC with stages I, I-II, I-III, and III, body weight ≤ 80kg, or > 80kg, height, BMI, G2-3 grade, endometrioid, tumor invasion, age ≥ 60 years, hormone therapy (no), radiotherapy (no), diabetes (yes or no).